Display Settings:

Format

Send to:

Choose Destination

Hereditary Folate Malabsorption.

Source

GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
2008 Jun 17 [updated 2014 Jun 05].

Excerpt

DISEASE CHARACTERISTICS:

Hereditary folate malabsorption (HFM) is characterized by folate deficiency with impaired intestinal folate absorption and impaired folate transport into the central nervous system (CNS). Findings include poor feeding and failure to thrive, anemia often accompanied by leukopenia and/or thrombocytopenia, diarrhea and/or oral mucositis, hypoimmunoglobulinemia, and other immunologic dysfunction resulting in infections with unusual organisms. Neurologic manifestations include developmental delays, cognitive and motor impairment, behavioral disorders and, frequently, seizures.

DIAGNOSIS/TESTING:

Diagnosis of HFM is confirmed by impaired absorption of an oral folate load and low cerebrospinal fluid (CSF) folate concentration (even after correction of the serum folate concentration). SLC46A1, encoding the proton-coupled folate transporter (PCFT) protein, a member of the superfamily of solute carriers, is the only gene known to be associated with HFM. Sequence analysis has identified either homozygous or compound heterozygous pathogenic variants in all clinically affected individuals to date.

MANAGEMENT:

Treatment of manifestations: Parenteral (intramuscular) or high-dose oral 5-formyltetrahydrofolate (5-formylTHF, folinic acid, Leucovorin®) can obviate the signs and symptoms of HFM. Dosing is aimed at achieving CSF folate trough concentrations as close as possible to the normal range for the age of the affected individual (infants and children have higher CSF folate levels than adults). Folic acid should not be used for the treatment of HFM because it binds very tightly to the folate receptor, therefore potentially blocking transport of physiologic folates across the choroid plexus. Prevention of primary manifestations: Early treatment readily corrects the systemic folate deficiency and achieves sufficient CSF folate levels to prevent the neurologic consequences of HFM. Prevention of secondary complications: In affected individuals with selective IgA deficiency, appropriate precautions for blood product transfusion should be taken. Surveillance: To assess adequacy of treatment, surveillance should include: periodic complete blood counts; measurements of serum and CSF folate concentrations; measurements of serum and CSF homocysteine concentrations; and monitoring of the affected individual’s neurologic status. Serial measurement of immunoglobulins is not necessary once the levels return to the normal range and serum folate and hemoglobin levels remain normal and stable. Evaluation of relatives at risk: For at-risk sibs, molecular genetic testing when the family-specific pathogenic variant(s) are known; otherwise, assessment of blood and CSF folate levels and, if warranted, intestinal absorption of folate immediately after birth, or as soon as the diagnosis is confirmed in the proband. Pregnancy management: Affected women should increase their folate intake above the maintenance dose prior to attempting to conceive; infants with HFM do not appear to be at an increased risk for malformations typically associated with maternal folate deficiency during pregnancy.

GENETIC COUNSELING:

HFM is inherited in an autosomal recessive manner. Heterozygotes (carriers) are asymptomatic and do not have clinical signs of folate deficiency. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. If both pathogenic variants have been identified in the family, carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk may be available from a clinical laboratory that offers either testing for this disease/gene or custom testing.

Copyright © 1993-2014, University of Washington, Seattle. All rights reserved.

PMID:
20301716
[PubMed]
Books & DocumentsFree full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Write to the Help Desk